Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dermatophagoides farinae mannan-conjugated polymerized allergoid
- Development stage
- Unknown
- Lead developer
- Inmunotek
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Dermatophagoides farinae mannan-conjugated polymerized allergoid is a next-generation allergen immunotherapy (AIT) developed by Inmunotek. It consists of allergoids—allergens chemically modified and polymerized with glutaraldehyde to reduce IgE-mediated allergenicity while preserving T-cell immunogenicity—conjugated to mannan derived from *Saccharomyces cerevisiae*. This mannan conjugation specifically targets the mannose receptor (CD206) on dendritic cells (DCs), facilitating efficient allergen uptake and processing. This targeted delivery promotes a shift in the immune response from a Th2-mediated allergic profile toward a Th1 and regulatory T-cell (Treg) response, thereby inducing clinical tolerance. It is primarily indicated for the treatment of allergic rhinitis, allergic rhinoconjunctivitis, and controlled allergic asthma in patients sensitized to the house dust mite *Dermatophagoides farinae*.
- Brand names
- Acarovac PlusAcarovac
- Other names
- Dermatophagoides farinae mannan-conjugated allergoidMannan-conjugated polymerized allergoid of Dermatophagoides farinae
02
Targets
MRC1 (Mannose Receptor C-type 1)
Beyond the preview
Go deeper on dermatophagoides farinae mannan-conjugated polymerized allergoid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dermatophagoides farinae mannan-conjugated polymerized allergoid.